FDAnews Drug Daily Bulletin

Dyax Strikes Deal for Chinese Sales of Drug

Feb. 8, 2013
A A
Dyax of Burlington said it is partnering with CVie Therapeutics to develop and commercialize its drug Kalbitor in China, Hong Kong and Macau. Kalbitor is used to treat hereditary angioedema, a rare, genetic condition affecting the immune system that causes swelling of the face and airways, abdominal cramping and other angioedema indications.
Boston Herald